ABBV vs ABT
AbbVie Inc. vs Abbott Laboratories · Updated Mar 28, 2026
ABBV — 13 winsABT — 8 wins
Price Performance
ABBV +2.00%ABT -20.51%
Performance
| ABBV | ABT | |
|---|---|---|
| 1 Month | -6.60% | -9.19% |
| 3 Months | -8.71% | -16.32% |
| 6 Months | -3.97% | -22.17% |
| YTD | -8.15% | -16.82% |
| 1 Year | +4.25% | -17.03% |
| 3 Year | +36.57% | +5.98% |
| 5 Year | +98.17% | -13.34% |
Yearly Returns
| YTD | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ABBV | -8.7% | +27.3% | +11.2% | -4.6% | +19.3% | +28.4% | +19.6% | -0.8% | -6.3% | +55.0% | +8.7% | -10.1% |
| ABT | -16.3% | +10.4% | +3.0% | +0.5% | -21.0% | +29.0% | +25.9% | +25.0% | +23.0% | +46.1% | -10.5% | +0.0% |
Valuation
| ABBV | ABT | |
|---|---|---|
| P/E Ratio | 88.92 | 27.94 |
| Forward P/E | 14.13 | 19.00 |
| PEG Ratio | 7.81 | 2.86 |
| P/S Ratio | 5.93 | 4.14 |
| P/B Ratio | — | 3.48 |
| EV/EBITDA | 14.91 | 16.15 |
Financials
| ABBV | ABT | |
|---|---|---|
| EPS (TTM) | $2.36 | $3.73 |
| Gross Margin | +72.61% | +57.05% |
| Operating Margin | +27.34% | +19.64% |
| Net Margin | +10.93% | +15.50% |
| ROE | -131.16% | +12.36% |
| ROA | +3.16% | +7.52% |
| Debt/Equity | -19.98 | 0.25 |
Growth
| ABBV | ABT | |
|---|---|---|
| Revenue Growth YoY | +10.04% | +4.42% |
| Revenue Growth QoQ | +5.34% | +0.79% |
| EPS Growth YoY | +5735.36% | -80.61% |
| EPS Growth QoQ | +920.00% | +8.51% |
Technical
| ABBV | ABT | |
|---|---|---|
| RSI (14) | 35.84 | 35.55 |
| % From 20-Day SMA | -4.43% | -4.46% |
| % From 50-Day SMA | -5.35% | -6.40% |
| % From 200-Day SMA | -2.72% | -16.68% |
| % From 52-Week High | -14.28% | -25.06% |
| % From 52-Week Low | +27.66% | +1.76% |
Analyst Ratings
ABBV
Buy(20 analysts)
Strong SellHoldStrong Buy
Price Target
$256.15
+25.90% upside
ABT
Buy(19 analysts)
Strong SellHoldStrong Buy
Price Target
$137.67
+29.55% upside
Overview
| ABBV | ABT | |
|---|---|---|
| Sector | Healthcare | Healthcare |
| Industry | Drug Manufacturers - General | Medical - Devices |
| Exchange | NYSE | NYSE |
| Market Cap | $362.60B | $183.43B |
| Shares Outstanding | 1.77B | 1.74B |
| Avg Volume (10D) | 7.99M | 15.85M |
| Dividend Yield | 3.24% | 2.27% |
Frequently Asked Questions
Is ABBV or ABT a better buy right now?
Based on 21 comparable metrics, ABBV leads in 13 categories while ABT leads in 8. ABBV has a consensus analyst rating with 20 analysts covering the stock. Neither stock should be purchased based on a single comparison — consider your investment goals and risk tolerance.
Which stock has better performance, ABBV or ABT?
Over the past year, ABBV returned +4.25% compared to ABT's -17.03%. In the short term (1 month), ABBV returned -6.60% vs ABT's -9.19%.
Is ABBV or ABT more expensive?
ABBV trades at a P/E of 88.92 compared to ABT's 27.94. On a price-to-sales basis, ABBV trades at 5.93x vs ABT's 4.14x. Forward P/E: ABBV at 14.13 vs ABT at 19.00.
Which stock has higher growth, ABBV or ABT?
ABBV's revenue grew +10.04% year-over-year compared to ABT's +4.42%. EPS growth: ABBV at +5735.36% vs ABT at -80.61%.
Do ABBV and ABT pay dividends?
ABBV pays a dividend with a yield of 3.24%. ABT pays a dividend with a yield of 2.27%.
Which stock do analysts prefer, ABBV or ABT?
ABBV has 20 analysts with a target price of $256.15 (+25.90% upside). ABT has 19 analysts with a target of $137.67 (+29.55% upside).
Data updated daily. All comparisons based on latest available market data. Not investment advice.